Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Prednisone placebo Clear all
Active, not recruiting Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Drug
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Sep 27, 2026, 4:49 AM EDT
Terminated Phase 4 Interventional

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

NCT00656266
View directory record Official record
Conditions
End-stage Liver Disease, Renal Insufficiency, Renal Failure
Interventions
mycophenolate mofetil, placebo medication
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 16 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 27, 2026, 4:49 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853
View directory record Official record
Conditions
Hormone-Sensitive Prostate Cancer
Interventions
Capivasertib, Placebo, Abiraterone Acetate
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Tucson, Arizona • La Jolla, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 1 Interventional

Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus

NCT02872597
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 4 Interventional

Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma

NCT01241006
View directory record Official record
Conditions
Asthma, Reactive Airway Disease
Interventions
Dexamethasone, Prednisone
Drug
Lead sponsor
Alameda County Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

NCT00774852
View directory record Official record
Conditions
Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions
abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 4 Interventional Results available

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

NCT00443430
View directory record Official record
Conditions
Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Interventions
methotrexate, methotrexate - etanercept - prednisolone arm
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Not applicable Interventional Results available

Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis

NCT01671423
View directory record Official record
Conditions
Cellulitis
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 27, 2026, 4:49 AM EDT
Active, not recruiting Phase 3 Interventional Results available

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02257736
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Abiraterone acetate, Prednisone, Placebo
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
46
States / cities
Phoenix, Arizona • La Mesa, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

NCT00556439
View directory record Official record
Conditions
Takayasu's Arteritis, Giant Cell Arteritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
15 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

NCT04598451
View directory record Official record
Conditions
Pemphigus Vulgaris, Pemphigus Foliaceus
Interventions
efgartigimod PH20 SC, Placebo, prednisone
Biological · Other · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 27, 2026, 4:49 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy of Prednisone In the Treatment of Ocular Myasthenia

NCT00995722
View directory record Official record
Conditions
Ocular Myasthenia Gravis
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Michael Benatar
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
New Haven, Connecticut • Miami, Florida • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00110214
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
docetaxel, placebo, prednisone, bevacizumab, laboratory biomarker analysis
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

NCT01791153
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 27, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

NCT03207815
View directory record Official record
Conditions
Noninfectious Uveitis
Interventions
Filgotinib, Placebo to match filgotinib, Prednisone
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
15
States / cities
Palo Alto, California • Golden, Colorado • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

NCT02767089
View directory record Official record
Conditions
Healthy Adults
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

NCT01086540
View directory record Official record
Conditions
Systemic Sclerosis-Associated PAH
Interventions
Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
Biological · Other · Diagnostic Test + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

NCT01369745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Prednisolone, dipyridamole, Prednisone, Z102, placebo
Drug · Other
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 4 Interventional Results available

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

NCT00221299
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Parathyroid Hormone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 27, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

NCT07060638
View directory record Official record
Conditions
Alcohol-associated Hepatitis
Interventions
IL-22, Prednisone, Acamprosate, Prednisone placebo, IL-22 (F-652) Placebo, Motivational Interviewing (MI), Motivational Enhancement Therapy (MET), Usual Care
Drug · Behavioral
Lead sponsor
Samer Gawrieh
Other
Eligibility
18 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

NCT03312907
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

NCT00104299
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions
Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 27, 2026, 4:49 AM EDT
Completed Phase 2 Interventional

Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy

NCT00004448
View directory record Official record
Conditions
IgA Glomerulonephritis
Interventions
omega-3 fatty acids, prednisone, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Up to 40 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 27, 2026, 4:49 AM EDT
Terminated Phase 3 Interventional Results available

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

NCT01522443
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
Interventions
cabozantinib, mitoxantrone, prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
49
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 27, 2026, 4:49 AM EDT